Clinicopathological MRI and CSF Correlates in Huntington's Disease.

Sponsor

Leiden University Medical Center (Other)

Overall Status

Recruiting

CT.gov ID

NCT05534139

Collaborator

Brighton & Sussex Medical School (Other), University of Ulm (Other)

Enrollment

Location

36.7

Anticipated Duration (Months)

2.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

In this study the investigators will link brain iron levels obtained from quantitative susceptibility maps of HD patients with specific and well-known clinical CSF markers for iron accumulation, neurodegeneration and neuroinflammation. The relationship between iron accumulation and neuroinflammation, and the clinical and genetic characteristics of HD will be investigated. This will provide an important basis for the evaluation of brain iron levels as an imaging biomarker for disease state in HD and their relationship with the salient pathomechanisms of the disease.

Condition or Disease	Intervention/Treatment	Phase
Huntington Disease	Diagnostic Test: 7T MRI-scan Diagnostic Test: CSF collection via lumbar puncture Diagnostic Test: Blood withdrawal Diagnostic Test: Clinical measures

Detailed Description

This investigator-initiated, single-site cross-sectional study looks at iron accumulation using 7T MR-imaging, CSF and blood. This will be achieved in a two-day visit involving clinical assessments, MRI-scanning of the brain, followed by a lumbar puncture the next day, after overnight fasting. Sixty-five volunteers with HD and 25 volunteers without HD will be included. Of these 65 volunteers with HD, 25 will be premanifest, 20 early manifest and 20 moderate manifest, in order to cover the wide-spectrum of Huntington's Disease.

Study Design

Study Type:

Observational

Anticipated Enrollment :

90 participants

Observational Model:

Case-Control

Time Perspective:

Cross-Sectional

Official Title:

Clinicopathological MRI and CSF Correlates of Iron Accumulation, Neurodegeneration and Neuroinflammation in Huntington's Disease.

Actual Study Start Date :

Aug 11, 2021

Anticipated Primary Completion Date :

Aug 31, 2023

Anticipated Study Completion Date :

Aug 31, 2024

Arms and Interventions

Arm	Intervention/Treatment
Healthy controls Partner/spouse of a patient not at risk of HD OR sibling with genetic test results available that show a normal CAG repeat length for both HTT alleles (<36); No other known cognitive, neurological or psychiatric disorders.	Diagnostic Test: 7T MRI-scan MRI-scanning of the brain using a 7T-MRI scanner Diagnostic Test: CSF collection via lumbar puncture CSF is collected by doing a lumbar puncture Diagnostic Test: Blood withdrawal Blood is collected by doing a blood withdrawal Diagnostic Test: Clinical measures UHDRS-Total motor score, UHDRS-short problem behaviour assessment, UHDRS-Cognitive assessments
Premanifest HD expanded gene carrier HDGEC before clinical onset: TMS <5, DCL <4, TFC = 13. No other major comorbidity.	Diagnostic Test: 7T MRI-scan MRI-scanning of the brain using a 7T-MRI scanner Diagnostic Test: CSF collection via lumbar puncture CSF is collected by doing a lumbar puncture Diagnostic Test: Blood withdrawal Blood is collected by doing a blood withdrawal Diagnostic Test: Clinical measures UHDRS-Total motor score, UHDRS-short problem behaviour assessment, UHDRS-Cognitive assessments
Early Manifest HD patient HDGEC after clincial onset: TMS >5, DCL = 4. Early stage of disease: TFC 11-13. No other major comorbidity.	Diagnostic Test: 7T MRI-scan MRI-scanning of the brain using a 7T-MRI scanner Diagnostic Test: CSF collection via lumbar puncture CSF is collected by doing a lumbar puncture Diagnostic Test: Blood withdrawal Blood is collected by doing a blood withdrawal Diagnostic Test: Clinical measures UHDRS-Total motor score, UHDRS-short problem behaviour assessment, UHDRS-Cognitive assessments
Moderate Manifest HD patient HDGEC after clincial onset: TMS >5, DCL = 4. Moderate stage of disease: TFC 7-10. No other major comorbidity.	Diagnostic Test: 7T MRI-scan MRI-scanning of the brain using a 7T-MRI scanner Diagnostic Test: CSF collection via lumbar puncture CSF is collected by doing a lumbar puncture Diagnostic Test: Blood withdrawal Blood is collected by doing a blood withdrawal Diagnostic Test: Clinical measures UHDRS-Total motor score, UHDRS-short problem behaviour assessment, UHDRS-Cognitive assessments

Outcome Measures

Primary Outcome Measures

Quantified Susceptibility Mapping [At baseline]
MRI analysis to quantify iron accumulation
Iron in CSF [At baseline]
Amount of iron and ferritin measured in CSF

Secondary Outcome Measures

Iron in blood [At baseline]
Amount of iron and ferritin measured in blood
Clinical motor signs [At baseline]
Motor signs obtained using the Unified Huntington's Disease Rating Scale - Total Motor Score. This is a scale assessing motor symptoms of HD, ranging from a score of 0 to 124, where higher scores mean a worse outcome.
Neuroinflammation and neurodegeneration biomarkers in CSF [Baseline]
a.o. NFL: pg/mL CHIT1: pg/mL IL-6: pg/mL
Neuroinflammation and neurodegeneration biomarkers in CSF [Baseline]
- YKL-40: ng/mL
Cognitive score [At baseline]
Assessment of cognitive tests.
Neuropsychiatric symptoms [At baseline]
Assessment of short Problem Behaviour Assessment. Each symptom is rated for severity on a 5-point scale : 0 = "not at all"; 1 = trivial; 2 = mild; 3 = moderate (disrupting everyday activities) and 4 = severe or intolerable. Each symptom is also scored for frequency on a 5-point scale as follows: 0 = symptom absent; 1 = less than once weekly; 2 = at least once a week; 3 = most days (up to and including some part of everyday); and 4 = all day, every day. Severity and frequency scores are multiplied to produce an overall 'PBA score' for each symptom.

Eligibility Criteria

Criteria

Ages Eligible for Study:

21 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Native Dutch/Flemish speaker
Ability to undergo MRI scanning;
Written informed consent must be obtained from the participant.

And in addition:

If the participant is a pre-manifest HD gene carrier:

CAG expansion ≥ 40;
UHDRS Total Motor Score (TMS) ≤ 5;
Total Functional Capacity (TFC) = 13;
Diagnostic Confidence Score < 4.

If the participant is an early-manifest HD gene carrier:

CAG expansion ≥ 36;
Diagnostic Confidence Score = 4;
HD stage I: TFC scores between 11 and 13 inclusive.

If the participant is a moderate manifest HD gene carrier:

CAG expansion ≥ 36;
Diagnostic Confidence Score = 4;
HD stage II: TFC scores between 7 and 11 inclusive.

If the participant is a control subject:

Partner/spouse of a patient not at risk of HD OR sibling with genetic test results available that show a normal CAG repeat length for both HTT alleles (<36);
No other known cognitive, neurological or psychiatric disorders.

Exclusion Criteria:

Additional major comorbidities not related to HD (e.g. cardiovascular diseases, coagulopathy, hypertension, diabetes mellitus, and/or other neurological disorders);
History of severe head injury;
Status of the participant after brain surgery;
Past erythrocyte transfusions;
Use of investigational drugs or participation in a clinical drug trial within 30 days prior to study visit;
Current intoxication, drug or alcohol abuse or dependence;
Pregnancy;
Inability to understand the information about the protocol;
Severe physical restrictions (completely wheelchair dependent);
Severe chorea that, in the investigator's judgment, precludes the patient's participation in and completion of the MRI and/or lumbar puncture.
Contra-indication to MRI scanning, such as:
Claustrophobia;
Pacemakers and defibrillators;
Nerve stimulators;
Intracranial clips;
Intraorbital or intraocular metallic fragments;
Cochlear implants;
Ferromagnetic implants;
Hydrocephalus pump;
Intra-utrine device (not all types);
Permanent make-up;
Tattoos above the shoulders (not all).
Contraindications for a lumbar puncture, including:
Screening blood test results outside normal ranges(white cell count, neutrophil count, lymphocyte count, hemoglobin, platelets, Prothrombin time (PT), activated partial thromboplastin time (APTT), C-reactive protein (CRP) and serum ferritin) if only marginally decreased or increased this will be decided by the clinical PI;
Signs and symptoms of increased intracranial pressure which will be confirmed on the 7T MRI (T1 and FLAIR scan) or by a fundoscopy;
Local infections of the skin;
Use of anti-coagulant drugs within the last 14 days prior lumbar puncture.